Skip to main content
Delfa

← All trials/NCT07706088

T-DPN

Not yet recruitingPhase 4

Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy

Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy: A Randomized, Open Label, Controlled Study

Asset

Tirzepatide

Subcutaneous · GLP-1 / GIP dual

Listed sites

0

Recruiting sites

-

Estimated enrollment

40

Study population

-

Eligibility highlights

•BMI ≥27•HbA1c 7-10%

Primary endpoint

-

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07706088
Org study ID001

Timeline

Milestones

Study first posted2026-07-15actual
Last update posted2026-07-15actual
Primary completion2028-07-01estimated
Study completion2028-07-01estimated
Study start2026-07estimated (month precision)

Assets

Investigational agents

Tirzepatide

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

Eligible participants (≥ 18 years) with diabetes duration of < 10 years, baseline HbA1c between 7% and 10% Signs and symptoms of DSPN based on a Michigan Neuropathy Screening Instrument (MNSI) history composite score of >= 7 OR MNSI examination SCORE >= 2.5 will be enrolled.

BMI >= 27 KG/metre 2.

Exclusion criteria

1. participants with untreated hypothyroidism

2. history of leprosy

3. peripheral vascular disease defined by ankle-brachial index (ABI) \&lt; 0.9

4. serum B12 levels < 200 pg./mL/ if low will be supplemented

5. history of alcohol excess (>=2 and >= 1 standard drink per day for male and female respectively)

6. any condition affecting corneal nerves (severe dry eyes, severe corneal dystrophies, ocular trauma or surgery in the preceding 6 months or Sjogren\&#39;s or sicca syndrome

7. use of oral contraceptives.

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.